MARKET

INO

INO

Inovio Pharmaceu
NASDAQ
11.31
+0.27
+2.45%
After Hours: 11.31 0 0.00% 19:54 07/12 EDT
OPEN
11.15
PREV CLOSE
11.04
HIGH
11.72
LOW
10.86
VOLUME
552.59K
TURNOVER
0
52 WEEK HIGH
14.75
52 WEEK LOW
3.888
MARKET CAP
293.05M
P/E (TTM)
-2.0427
1D
5D
1M
3M
1Y
5Y
1D
Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More
Home Stock Ideas Quick Picks & Lists Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More. This edition of the 'Undercovered' Dozen highlights twelve ideas from June 28th - July 11th on stocks with limited coverage. Newmont Corporation and Teck Resources are highlighted as a pair trade in the Industrials space. Evergy faces risks in the AI data center market, but could benefit from chip proliferation.
Seeking Alpha · 1d ago
Inovio Pharmaceuticals Receives ‘Buy’ Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
TipRanks · 2d ago
INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis. Inovio's lead DNA medicine candidate has been designated an innovative medicine in the U.K.
Benzinga · 2d ago
Weekly Report: what happened at INO last week (0701-0705)?
Weekly Report · 6d ago
Inovio Pharmaceuticals: Upcoming BLA Is Critical
Inovio Pharmaceuticals is on track for filing its BLA for INO-3107 in the latter half of 2024. Inovio has little in the way of pipeline support. Expect significant dilution as inovio proceeds with its BLa and anticipated approval and launch of the drug.
Seeking Alpha · 6d ago
Press Release: INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
Dow Jones · 07/02 20:05
Weekly Report: what happened at INO last week (0624-0628)?
Weekly Report · 07/01 09:26
Weekly Report: what happened at INO last week (0617-0621)?
Weekly Report · 06/24 09:28
More
About INO
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.